Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways

International Journal of Oncology

Volumn 12, Issue 4, 1998, Pages 793-804

  Liu, Weimin ^a   Zhang, Ruiwen ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Camptothecins; Chemotherapy; Human breast cancer; p21WAF1 CIP1; p53

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; DNA FRAGMENT; MESSENGER RNA; NATURAL PRODUCT; PROTEIN P21; PROTEIN P53; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DRUG DERIVATIVE; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CHRONOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; BIOSYNTHESIS; BREAST TUMOR; CELL CULTURE; DNA DAMAGE; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031594763     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.4.793     Document Type: Article

References (63)

1. American Cancer Society: Cancer Facts and Figures. American Cancer Society, Atlanta, 1993.
2. Zhang R, Cai Q, Lindsey JR, Li Y, Chambless B and Naguib FNM: Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts. Int J Oncol 10: 1147-1156, 1997.
3. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
4. Wall ME and Wani MC: Camptothecin and analogs: from discovery to clinic. In: Camptothecins: New Anticancer Agents. Potmesol M and Pinedo H (eds). CRC Press, Boca Raton, FL, pp21-41, 1995.
5. Muggia FM, Creaven PJ, Hansen HH, Cohen MH and Selawry OS: Phase I clinical trial weekly and daily treatment of camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515-521, 1972.
6. Moertel CG, Schutt AJ, Reitemeier RJ and Hahn RG: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972.
7. Gottlieb JA and Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103-105, 1972.
8. Panpazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR and Giovanella BC: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of non-tumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53: 1577-1582, 1993.
9. Potmesil M and Giovanella BC: Preclinical development of , 20(S)-camptothecin, 9-aminocamptothecin, and other analogues. In: Camptothecins: New Anticancer Agents. Potmesol M and Pinedo H (eds). CRC Press, Boca Raton, FL, pp41-57, 1995.
10. Cai Q, Lindsey JR and Zhang R: Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins. Intl J Oncol 10: 953-960, 1997.
11. Wani MC and Wall ME: Plant antitumor agents II. The structure of two new alkaloids from Camptotheca acuminata. J Org Chem 51: 1364-1367, 1969.
12. Ling Y-H, Perez-Soler R and Tseng MT: Effect of DNA topoisomerase I inhibitor, 10-hydroxycamptothecin, on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells. Anticancer Res 13: 1613-1618, 1993.
13. Ling Y-H and Xu B: Inhibition of phosphorylation of histone Hl and H3 induced by 10-hydroxycamptothecin, DNA topo-isomerase I inhibitor, in murine ascites hepatoma cells. Acta Pharmacol Sin 14: 546-550, 1993.
14. Vaux DL and Strasser A: The molecular biology of apoptosis. Proc Natl Acad Sci USA 93: 2239-2244, 1996.
15. Denmeade SR and Isaacs JT: Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 3: 303-309, 1996.
16. Gong J, Li X and Darzynkiewicz Z: Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin. J Cell Physiol 157: 263-270, 1993.
17. Bino DG, Skierski JS and Darzynkiewicz Z: Apoptotic cell death triggered by camptothecin or teniposide: the cell cycle specificity and effects of ionizing radiation. Cell Proliferation 25: 537-548, 1992.
18. Li X, Traganos F and Darzynkiewicz Z: Simultaneous analysis of DNA replication and apoptosis during treatment of HL-60 cells with camptothecin and hyperthermia and mitogen stimulation of human lymphocytes. Cancer Res 54: 4289-4293, 1994.
19. Solary E, Bertrand R, Kohn KW and Pommier Y: Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81: 1359-1368, 1993.
20. Bertrand R, Solary E, Jenkins J and Pommier Y: Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res 207: 388-397, 1993.
21. Bicknell GR, Snowden RT and Cohen GM: Formation of high molecular mass DNA fragments is a marker of apoptosis in the human leukaemia cell line, U937. J Cell Sci 107: 2483-2489, 1994.
22. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB and Schneider E: Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 55: 2122-2128, 1995.
23. Tanizawa A, Fujimori A, Fujimori Y and Pommier Y: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836-842, 1994.
24. Pantazis P, Early JA, Mendoza JT, deJesus AR and Giovanella BC: Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 54: 771-776, 1994.
25. Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T and Kizaki H: Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim Biophys Acta 1175: 147-154, 1993.
26. Binaschi M, Zunino F and Capranico G: Mechanism of action of DNA topoisomerase inhibitors. Stem Cells 13: 369-379, 1995.
27. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
28. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597, 1992.
29. Hollstein MD, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
30. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
31. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
32. Di Leonardo A, Linke SP, Clarkin K and Wahl GM: DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cipl in normal human fibroblasts. Genes Dev 8: 2540-2551, 1994.
33. Kuerbits SJ, Plundett BS, Walsh WV and Kastan MB: Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
34. Wu X, Bayle JH, Olson D and Levine AJ: The p53-mdm2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993.
35. Fornace AJ, Nebert DW, Hollander MC, Luethy JD, Papathanasiou MA, Fargnoli J and Holbrook NJ: Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 9: 4196-4203, 1989.
36. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Volgelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
37. Harper JW, Adami GR, Wei N, Keyonarsi K and Elledge SJ: The p21 cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
38. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
39. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
40. Li R, Waga S, Hannon GJ, Beach D and Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371: 534-537, 1994.
41. Carmichael J, deGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a Tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
42. Dubrez F, Goldwasser F, Genne P, Pommier Y and Solary E: The role of cell regulation and apoptosis triggering in determing the sensitivity of leukemic cells to topoisomerase I an II inhibitors. Leukemia 9: 1013-1024, 1995.
43. Gong J, Traganos F and Darzynkiewicz Z: A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 314-319, 1994.
44. Gartenhaus RB, Wang P and Hoffmann P: Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc Natl Acad Sci USA 93: 265-268, 1996.
45. Chomczynski P and Sacchi N: Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 132: 6-13, 1987.
46. Nelson WG and Kastan MB: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994.
47. Tishler RB, Calderwood SK, Coleman CN and Price BD: Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212-2216, 1993.
48. Slingerland JM, Minden MD and Benchimol S: Mutation of the p53 gene in human acute myelogenous leukemia. Blood 77: 1500-1507, 1991.
49. Gaidano G, Ballerimi P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM and Dalla-Favera R: p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88: 5413-5417, 1991.
50. Bartek J, Iggo R, Gannon J and Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893-899, 1990.
51. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-707, 1989.
52. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B and Veronesi U: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1,400 node-negative breast cancers. Clin Cancer Res 2: 2007-2013, 1996.
53. Maltzman W and Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689-1694, 1984.
54. Chen L, Agrawal S, Zhou W, Zhang R and Chen J: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 95: 195-200, 1998.
55. Gottlieb TM and Jackson SP: The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 72: 131-142, 1993.
56. Bruno S, Lassota P, Giaretti W and Darzynkiewicz Z: Inhibitors of proteases prevent endonucleolysis accompanying apoptotic cell death. Leukemia 6: 1113-1120, 1992.
57. Suzanne C: Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 13: 513-543, 1995.
58. Sinicrope FA, Ruan S, Cleary KR, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
59. Oltvai Z, Milliman C and Korsmeyer SJ: Bcl-2 heterodimerizes /ii vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
60. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395, 1994.
61. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11: 493-504, 1995.
62. WAF1/CIP1 growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11: 1899-1905, 1995.
63. WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res 56: 5055-5062, 1996.